Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,624.70
(
-1.36%
)
US TECH 100
23,693.60
(
-0.43%
)
Dow Jones
46,225.15
(
-1.63%
)
Brent Oil
111.51
(
4.62%
)
Bitcoin
70,494.07
(
-1.05%
)
News Focus
News Focus
Post# of 257257
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (3) Keep Next 10 Report Keyboard Shortcuts
Replies (3) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 842
Posts 122795
Boards Moderated 10
Alias Born 09/05/2002

DewDiligence

Member Level

Re: iwfal post# 113145

Tuesday, 01/25/2011 2:13:21 PM

Tuesday, January 25, 2011 2:13:21 PM

Post# of 257257
Goldman Sachs just issued a report saying that the non-approval MNTA received in Nov 2007 relating to Lovenox immunogenicity was a Minor Deficiency letter. This is contrary to my understanding of what happened, but I thought it was worth mentioning.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (3) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (3) Next 10 Prev Next

Trade Smarter with Thousands

Leverage decades of market experience shared openly.

Join Now